These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 10871299)

  • 41. St. John's wort: role of active compounds for its mechanism of action and efficacy.
    Butterweck V; Schmidt M
    Wien Med Wochenschr; 2007; 157(13-14):356-61. PubMed ID: 17704987
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanism of action of St John's wort in depression : what is known?
    Butterweck V
    CNS Drugs; 2003; 17(8):539-62. PubMed ID: 12775192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antidepressant activity of hyperforin conjugates of the St. John's wort, Hypericum perforatum Linn.: an experimental study.
    Muruganandam AV; Bhattacharya SK; Ghosal S
    Indian J Exp Biol; 2001 Dec; 39(12):1302-4. PubMed ID: 12018529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of German St. John's wort products according to hyperforin and total hypericin content.
    Wurglics M; Westerhoff K; Kaunzinger A; Wilke A; Baumeister A; Dressman J; Schubert-Zsilavecz M
    J Am Pharm Assoc (Wash); 2001; 41(4):560-6. PubMed ID: 11486982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Cellular and molecular effects of the antidepressant hyperforin on brain cells: Review of the literature].
    Bouron A; Lorrain E
    Encephale; 2014 Apr; 40(2):108-13. PubMed ID: 23816060
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wort.
    Wonnemann M; Singer A; Siebert B; Müller WE
    Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S148-51. PubMed ID: 11518066
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antagonist effect of pseudohypericin at CRF1 receptors.
    Simmen U; Bobirnac I; Ullmer C; Lübbert H; Berger Büter K; Schaffner W; Schoeffter P
    Eur J Pharmacol; 2003 Jan; 458(3):251-6. PubMed ID: 12504780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of pancreatic lipase by the constituents in St. John's Wort: In vitro and in silico investigations.
    Hou XD; Guan XQ; Cao YF; Weng ZM; Hu Q; Liu HB; Jia SN; Zang SZ; Zhou Q; Yang L; Ge GB; Hou J
    Int J Biol Macromol; 2020 Feb; 145():620-633. PubMed ID: 31883893
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An in vitro and hydroponic growing system for hypericin, pseudohypericin, and hyperforin production of St. John's wort (Hypericum perforatum CV new stem).
    Murch SJ; Rupasinghe HP; Saxena PK
    Planta Med; 2002 Dec; 68(12):1108-12. PubMed ID: 12494339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Involvement of serotoninergic 5-HT1A/2A, alpha-adrenergic and dopaminergic D1 receptors in St. John's wort-induced prepulse inhibition deficit: a possible role of hyperforin.
    Tadros MG; Mohamed MR; Youssef AM; Sabry GM; Sabry NA; Khalifa AE
    Behav Brain Res; 2009 May; 199(2):334-9. PubMed ID: 19136030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyperforin-containing extracts of St John's wort fail to alter gene transcription in brain areas involved in HPA axis control in a long-term treatment regimen in rats.
    Butterweck V; Winterhoff H; Herkenham M
    Neuropsychopharmacology; 2003 Dec; 28(12):2160-8. PubMed ID: 12865894
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?
    Gutmann H; Poller B; Büter KB; Pfrunder A; Schaffner W; Drewe J
    Planta Med; 2006 Jun; 72(8):685-90. PubMed ID: 16755466
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extracts of St. John's wort and various constituents affect beta-adrenergic binding in rat frontal cortex.
    Simbrey K; Winterhoff H; Butterweck V
    Life Sci; 2004 Jan; 74(8):1027-38. PubMed ID: 14672758
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content.
    Chrubasik-Hausmann S; Vlachojannis J; McLachlan AJ
    J Pharm Pharmacol; 2019 Jan; 71(1):129-138. PubMed ID: 29411879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Topical application of St John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells.
    Schempp CM; Winghofer B; Lüdtke R; Simon-Haarhaus B; Schöpf E; Simon JC
    Br J Dermatol; 2000 May; 142(5):979-84. PubMed ID: 10809859
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of St John's wort (hypericum perforatum) on cytochrome p450 1a2 activity in perfused rat liver.
    Dostalek M; Pistovcakova J; Jurica J; Sulcova A; Tomandl J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Sep; 155(3):253-7. PubMed ID: 22286810
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aqueous ethanolic extract of St. John's wort (Hypericum perforatum L.) induces growth inhibition and apoptosis in human malignant cells in vitro.
    Hostanska K; Reichling J; Bommer S; Weber M; Saller R
    Pharmazie; 2002 May; 57(5):323-31. PubMed ID: 12061257
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms of hepatocellular toxicity associated with the components of St. John's Wort extract hypericin and hyperforin in HepG2 and HepaRG cells.
    Abegg VF; Panajatovic MV; Mancuso RV; Allard JA; Duthaler U; Odermatt A; Krähenbühl S; Bouitbir J
    Toxicol Lett; 2024 Mar; 393():1-13. PubMed ID: 38219807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protective effects of St. John's wort extract and its component hyperforin against cytokine-induced cytotoxicity in a pancreatic beta-cell line.
    Menegazzi M; Novelli M; Beffy P; D'Aleo V; Tedeschi E; Lupi R; Zoratti E; Marchetti P; Suzuki H; Masiello P
    Int J Biochem Cell Biol; 2008; 40(8):1509-21. PubMed ID: 18226577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantitative analysis of the major constituents of St John's wort with HPLC-ESI-MS.
    Chandrasekera DH; Welham KJ; Ashton D; Middleton R; Heinrich M
    J Pharm Pharmacol; 2005 Dec; 57(12):1645-52. PubMed ID: 16354409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.